Immunotherapy regimens for metastatic colorectal carcinomas

Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related mortality with a 5-year overall survival rate of 13%. Despite recent advances in cancer immunotherapy, only the minority of CRC patients (<15%) with microsatellite instability can potentially benefit from immune checkpoint i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bashir, Babar, Snook, Adam E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806658/
https://www.ncbi.nlm.nih.gov/pubmed/29083978
http://dx.doi.org/10.1080/21645515.2017.1397244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806658/
https://www.ncbi.nlm.nih.gov/pubmed/29083978
http://dx.doi.org/10.1080/21645515.2017.1397244

Ejemplares similares